# Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

> **NCT00195208** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 97 (actual)

## Conditions studied

- Gastroesophageal Reflux
- Esophagitis

## Interventions

- **DRUG:** Pantoprazole for approximately 9 weeks

## Key facts

- **NCT ID:** NCT00195208
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195208, "Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00195208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*